GlassScriptPhysician profile
Robert W Mandal
NPI 1124012901
$6,122.45
in general payments reported to CMS, 2019-2025
42 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $158 · 2021: $288 · 2022: $1,383 · 2023: $1,108 · 2024: $1,317 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,145.16 | 2019-2025 | |
| Abbvie INC. | $521.16 | 2021-2025 | |
| Pfizer INC. | $453.78 | 2019-2025 | |
| Gilead Sciences, INC. | $399.05 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $320.41 | 2020-2025 | Keytruda, Lynparza |
| Celgene Corporation | $284.42 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $265.22 | 2022-2025 | Vyloy, Xospata, Xtandi |
| Daiichi Sankyo INC. | $196.13 | 2022-2025 | Enhertu, Datroway |
| Tempus Ai, INC | $187.04 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $180.70 | 2021-2023 | Imbruvica, Epkinly |
| Genentech USA, INC. | $155.78 | 2019-2023 | Venclexta, Perjeta, Phesgo |
| Glaxosmithkline, LLC. | $151.87 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $135.26 | 2019-2025 | Opdualag, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $113.61 | 2019-2025 | Alunbrig, Ninlaro |
| Astrazeneca Pharmaceuticals LP | $111.58 | 2020-2023 | Tagrisso |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $111.33 | 2021-2023 | Kyprolis, Vectibix, Xgeva |
| Blueprint Medicines Corporation | $108.88 | 2024-2025 | Ayvakit |
| Agios Pharmaceuticals, INC. | $105.44 | 2020-2025 | Pyrukynd |
| G1 Therapeutics, INC. | $92.23 | 2022-2023 | Cosela |
| Deciphera Pharmaceuticals INC. | $88.38 | 2022-2025 | Qinlock, Romvimza |
| Genzyme Corporation | $84.50 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $83.04 | 2021-2025 | Xpovio |
| Exelixis INC. | $79.50 | 2019 | |
| Eisai INC. | $77.99 | 2022-2024 | |
| Tersera Therapeutics LLC | $69.44 | 2024 | Zoladex, Xermelo |
| Janssen Pharmaceuticals, INC | $66.43 | 2020-2023 | Xarelto |
| Incyte Corporation | $61.68 | 2024-2025 | Jakafi, Monjuvi |
| Emd Serono, INC. | $56.61 | 2022 | |
| Alnylam Pharmaceuticals INC. | $49.70 | 2022-2023 | Givlaari |
| Array Biopharma INC | $46.91 | 2022-2025 | Lorbrena |
| Jazz Pharmaceuticals INC. | $43.53 | 2022 | |
| Lilly USA, LLC | $32.64 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $31.72 | 2022 | |
| Kite Pharma, INC. | $30.77 | 2025 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $29.20 | 2020 | |
| Taiho Oncology, INC. | $28.22 | 2023 | |
| Dendreon Pharmaceuticals LLC | $22.98 | 2022 | |
| Morphosys, US INC. | $22.61 | 2022 | |
| Geron Corporation | $21.97 | 2025 | Rytelo |
| Organon LLC | $20.83 | 2022 | |
| Puma Biotechnology, INC. | $18.64 | 2024 | |
| Bio Products Laboratory USA, INC. | $16.11 | 2023 | Gammaplex, Coagadex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mandal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.